Healthcare - Biotechnology - NASDAQ - US
$ 11.19
-5.65 %
$ 472 M
Market Cap
-3.79
P/E
INCOME STATEMENT
82.7 M
REVENUE
-65.5 M
OPERATING INCOME
-102 M
NET INCOME
EFFICIENCY
Earnings Waterfall
UroGen Pharma Ltd.
| Revenue | 82.7 M |
| Cost Of Revenue | 9.36 M |
| Gross Profit | 73.4 M |
| Operating Expenses | 139 M |
| Operating Income | -65.5 M |
| Other Expenses | 36.7 M |
| Net Income | -102 M |
Income Statement
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | Dec-2015 | Dec-2014 | Dec-2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | |||||||||||
| Revenue | 82.7 | 64.4 | 48.0 | 11.8 | 18 K | 1.1 | 8.2 | 17.5 | 0 | 0 | 0 |
| GROSS PROFIT | |||||||||||
| Cost Of Revenue | 9.4 | 7.7 | 5.2 | 1.0 | 0 | 1.8 | 0.6 | 28 K | 0.1 | 0 | 0 |
| Gross Profit | 73.4 | 56.7 | 42.9 | 10.8 | 18 K | (0.7) | 7.6 | 17.5 | (0.1) | 0 | 0 |
| OPERATING INCOME | |||||||||||
| Operating Expenses | 138.9 | 135.7 | 135.2 | 137.5 | 109.5 | 76.5 | 27.5 | 16.7 | 12.4 | 4.4 | 3.4 |
| Selling, General and Administrative Expenses | 93.3 | 82.8 | 87.5 | 90.2 | 60.2 | 39.6 | 8.8 | 6.4 | 1.9 | 0.9 | 1.1 |
| Research and Development Expenses | 45.6 | 52.9 | 47.6 | 47.3 | 49.3 | 36.9 | 18.7 | 10.3 | 10.5 | 4.0 | 2.3 |
| Operating Income | (65.5) | (79.0) | (92.3) | (126.7) | (109.5) | (77.2) | (19.9) | 0.8 | (12.4) | (4.4) | (3.4) |
| PRE-TAX INCOME | |||||||||||
| Interest Income Expense | 14.7 | 8.4 | 17.4 | 0.4 | 0.3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income | (32.8) | (29.0) | (17.1) | 1.6 | 4.3 | 1.6 | 31 K | (2.7) | (0.3) | (0.1) | 83 K |
| Pre-Tax Income | (98.3) | (108.0) | (109.4) | (125.1) | (105.1) | (75.5) | (20.0) | (1.9) | (12.7) | (4.5) | (3.3) |
| NET INCOME | |||||||||||
| Tax Provision | 3.9 | 1.1 | 1.4 | 3.4 | (4.6) | 0.1 | 19 K | 0 | 0 | 81 K | 0 |
| Net Income | (102.2) | (109.2) | (110.8) | (128.5) | (100.5) | (75.7) | (20.0) | (1.9) | (12.7) | (4.6) | (3.3) |
| EPS | 3.55 | 4.79 | 4.96 | 5.9 | 4.9 | 4.8 | 2.06 | 0.16 | 5.51 | 1.98 | 1.56 |